Stage IIIB Cutaneous Melanoma AJCC v7 Withdrawn Phase 1 / 2 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0091048 (Stage IIIB Cutaneous Melanoma AJCC v7)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03326258Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryTreatment